In an interview with Pharmacy Times, Ali A. Habib, MD, clinical professor of neurology at the University of California, Irvine, discusses what the hospitalization findings mean for patients and why they should be viewed as supportive evidence
|Videos|February 15, 2016
Solving the Puzzle of High Cost Specialty Drugs
Author(s)Davy James, Managing Editor
Jon Hamrick, executive vice president, Biotech and Specialty Services at Therigy LLC, discusses the implications of rising drug costs on specialty pharmacy.
Advertisement
Jon Hamrick, executive vice president, Biotech and Specialty Services at Therigy LLC, discusses the implications of rising drug costs on specialty pharmacy.
Advertisement
Related to this article
Eric Lawitz, MD, explains how pharmacists can raise liver risk with patients with obesity and why a FIB-4 score from routine blood work is a good first step.
The gap is not a paperwork inconvenience—it is a cash flow problem with clinical consequences.
Decades after cisplatin's approval, platinum-based chemotherapy continues to anchor treatment regimens across tumor types, new research finds.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Pneumonic Plague: What Pharmacists Need to Know About Treatment
2
FDA Approves First Once-Monthly Subcutaneous Olanzapine LAI for Adults With Schizophrenia
3
FDA Approves Pritelivir for Refractory HSV Lesions in Immunocompromised Adults
4
Could Cemdisiran Keep Patients With Myasthenia Gravis Out of the Hospital?
5